Vericel Stock Price, News & Analysis

Data published in the Journal of Burn Care & Research highlights a retrospective study on 40 patients with significant posterior burns treated with Epicel by the Burn and Reconstructive Centers of America. Key findings include an 83% engraftment success rate after one or two applications and a 90% survival rate. The study underscores the effectiveness of standardized treatment protocols for enhancing patient outcomes in severe burns. Epicel is approved for deep dermal or full-thickness burns covering at least 30% of total body surface area.

Vericel Corporation (NASDAQ:VCEL) will announce its second-quarter 2022 financial results on August 3, 2022, at 8:30 a.m. ET. The company specializes in advanced therapies for sports medicine and severe burn care, marketing MACI® and Epicel®, two cell therapy products. A conference call and webcast will follow the results announcement, accessible through their Investor Relations website. Vericel also holds the exclusive North American license for NexoBrid®, a product for severe thermal burns.

Vericel Corporation (NASDAQ:VCEL) reported a 4% increase in total net revenue to $36.1 million for Q1 2022, compared to $34.6 million in Q1 2021. MACI revenue was $26.0 million, while Epicel generated $9.9 million. The company's gross margin stood at 65%, down from 66% a year earlier. However, it experienced a net loss of $7.1 million or $0.15 per share, compared to $3.3 million in Q1 2021. Adjusted EBITDA decreased to $3.2 million. The company maintains its full-year guidance of $178 to $189 million in total revenue.

Vericel Corporation (NASDAQ:VCEL) will host a webcast and conference call on May 4, 2022, at 8:30 AM ET to discuss its Q1 2022 financial results and business highlights. The call will be accessible via the Investor Relations section of the company’s website. Vericel specializes in advanced therapies for sports medicine and severe burn care, offering cell therapy products such as MACI and Epicel, and has an exclusive license for NexoBrid in North America.

Vericel Corporation (NASDAQ:VCEL), known for its advanced therapies in sports medicine and severe burn care, announced that President and CEO Nick Colangelo will present at the Canaccord Genuity Musculoskeletal Conference in Chicago on March 22, 2022, at 11:00 a.m. Central Time. A webcast of the presentation will be accessible via the Investor Relations section of Vericel's website.

Vericel markets two primary cell therapy products: MACI®, for knee cartilage repair, and Epicel®, a skin replacement for severe burns. Additionally, the company holds rights to NexoBrid®, a product for burn debridement.

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will speak at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. ET. The event will be accessible via a webcast on the company's Investor Relations website.

Vericel focuses on advanced therapies for sports medicine and severe burn care, marketing MACI® for knee cartilage repair and Epicel® for severe burns treatment. The company also has rights to NexoBrid® for burn debridement, enhancing its product portfolio.

Vericel Corporation (NASDAQ:VCEL) appointed Jonathan Siegal as Principal Accounting Officer, effective February 16, 2022. Siegal, previously Vice President and Corporate Controller, joined Vericel in September 2021 and brings over 20 years of accounting experience across multiple industries. He held various leadership roles, including Global Controller for Lantheus Medical Imaging. CFO Joe Mara commended Siegal's extensive background in strengthening Vericel's finance team, reflecting the company’s commitment to enhancing its financial leadership.

Vericel Corporation (NASDAQ:VCEL) reported a 26% revenue growth in 2021, achieving total net revenue of $156.2 million. For Q4 2021, net revenue was $47.6 million, a 5% increase year-over-year. While MACI revenue reached $111.6 million and Epicel revenue hit $41.5 million, the company reported a net loss of $7.5 million for the year. Looking ahead, Vericel anticipates 2022 revenues between $178 million and $189 million with a gross margin of approximately 70%. A conference call is scheduled for today at 8:30 AM ET.

Vericel Corporation (NASDAQ:VCEL) announced a conference call on February 24, 2022 at 8:30 AM EST to discuss its fourth-quarter 2021 financial results and business highlights. The call will be accessible via the Investor Relations section of their website. Vericel specializes in advanced therapies in sports medicine and severe burn care, offering products like MACI® and Epicel®. A replay of the call will be available until February 28, 2022.